Sign in and upgrade to a paid plan to export dividends as CSV.
Sign in and upgrade to a paid plan to export dividends as CSV.

Pharmaids Pharmaceuticals Ltd.

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524572
₹29.40
▼ -0.42 (-1.41%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
23/100
Weak
Valuation
76/100
Undervalued
Momentum
45/100
Neutral

QVM read Cheap on its own multiples Quality Weak, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹104 Cr
PE (TTM)
Data unavailable.
Price to Book
2.2
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-49.3
Free Cash Flow
₹-9 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
149.19%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
67.68%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
222.28%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
2.51%
as of Dec. 31, 2024
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
1921.80%
as of March 31, 2026
Industry median 14.05% (173 companies)
Current Ratio
0.46
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.44
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
-1.00
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
-131.87%
as of Dec. 31, 2024
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
-40.59%
as of March 31, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-25.96%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-7.69%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
-15.59%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
-12.10%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 5 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.44)
  • No Return on equity is 15% or more (-12.1%)
  • Yes Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

1 of 5 met
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.4%
Low 29.3000 · High 30.4000
1W return
-2.4%
Low 29.0500 · High 30.7800
1M return
-7.5%
Low 29.0500 · High 33.9700
52W return
-49.3%
Low 29.0500 · High 36.8000
Lifetime High ₹75.4600 (Jan. 11, 2024)
Lifetime Low ₹1.5800 (March 9, 2009)

Full price history and technicals →

EMA & SMA

Bullish0
Bearish6
5D
29.7
10D
29.9
20D
30.6
50D
35.5
100D
41.3
200D
48.9

Delivery and volume

Day avg. delivery
55.8%
Week avg. delivery
73.6%
Month avg. delivery
75.7%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

29.70
Pivot
First resistance30.10
Second resistance30.80
Third resistance31.20
First support29.00
Second support28.60
Third support27.90
Day RSI34.8
Day MFI18.5
Day MACD-1.52
Day MACD signal-1.96

Beta

1M0.78
3M0.47
1Y0.47
3Y0.04

Price change analysis

↓ -7.5%
Over 1 Month
LowHigh
29.0533.97
↓ -49.3%
Over 3 Months
LowHigh
29.0536.80
↓ -49.3%
Over 6 Months
LowHigh
29.0536.80
↓ -49.3%
Over 1 Year
LowHigh
29.0536.80
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (June 30, 2026)
₹0 Cr
Net profit (June 30, 2026)
₹2 Cr
Basic EPS (June 30, 2026)
₹0.6100

Ranks #139 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter32.99%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 32.99% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
19 Dec 2022 EPITOME TRADING AND INVESTMENTS Bulk Buy 75,000 32.4500 BSE
19 Dec 2022 TOPGAIN FINANCE PRIVATE LIMITED Bulk Buy 80,000 32.4200 BSE
15 Dec 2022 TOPGAIN FINANCE PRIVATE LIMITED Bulk Buy 52,000 28.0500 BSE
15 Dec 2022 EPITOME TRADING AND INVESTMENTS Bulk Buy 60,456 29.3300 BSE
15 Dec 2022 MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED Bulk Sell 94,011 29.2800 BSE
14 Dec 2022 BP EQUITIES PVT. LTD. Bulk Buy 12 29.5000 BSE
14 Dec 2022 BP EQUITIES PVT. LTD. Bulk Sell 57,806 29.4900 BSE
14 Dec 2022 MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED Bulk Buy 94,011 28.9300 BSE
14 Dec 2022 EPITOME TRADING AND INVESTMENTS Bulk Buy 100,000 29.2900 BSE
26 Jul 2022 RAVI KUMAR KROVVIDI Bulk Sell 150,000 12.1000 BSE

All bulk and block deals →

Corporate Announcements

All 4 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
25 Sep 2026 Insider Trading / SAST Pharmaids Pharmaceuticals Ltd - 524572 - Closure of Trading Window
16 Sep 2026 Company Update Pharmaids Pharmaceuticals Ltd - 524572 - Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
15 Sep 2026 AGM/EGM Pharmaids Pharmaceuticals Ltd - 524572 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
11 Sep 2026 AGM/EGM Pharmaids Pharmaceuticals Ltd - 524572 - Shareholder Meeting / Postal Ballot-Outcome of AGM

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong revenue growth YoY (1921.8%)

Weaknesses

  • Low Return on Equity (-12.1%)
  • Thin net profit margin (-131.9%)
  • Tight liquidity (Current Ratio 0.46)

Opportunities

Data unavailable.

Threats

  • Down 49.3% over the past year
  • Weak interest coverage (-1.0x) -- limited cushion against rising rates

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Pharmaids Pharmaceuticals Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.